NVS logo

NVS
Novartis AG

6,727
Mkt Cap
$220.79B
Volume
0.00
52W High
$133.55
52W Low
$96.06
PE Ratio
18.75
NVS Fundamentals
50D MA
$127.51
Beta
0.26
Avg. Volume
1.19M
EPS (Annual)
$5.91
P/B
6.01
Rev/Employee
$662,711.55
Loading...
Loading...
News
all
press releases
Will Biogen Beat on Q3 Earnings? Leqembi, Skyclarys Could Hold the Key
Biogen is expected to top earnings forecasts again as new products offset declining multiple sclerosis drug sales.
Zacks·16h ago
News Placeholder
More News
News Placeholder
Incyte Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
INCY eyes strong Q3 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.
Zacks·17h ago
News Placeholder
REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?
Regeneron's Q3 earnings on Oct. 28 will likely spotlight Dupixent profits and strong Eylea HD uptake amid lingering Eylea competition.
Zacks·17h ago
News Placeholder
Lightning Round: I'm a buyer of Novartis, says Cramer
CNBC's Jim Cramer answers calls from viewers and offers advice for their stock picks...
CNBC Television-YouTube·1d ago
News Placeholder
Cramer's Lightning Round: Novartis is a buy
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed...
CNBC: Mad Money with Jim Cramer·1d ago
News Placeholder
Gear Up for Novartis (NVS) Q3 Earnings: Wall Street Estimates for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Novartis (NVS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
Zacks·2d ago
News Placeholder
Novartis (NVS) is an Incredible Growth Stock: 3 Reasons Why
Novartis (NVS) could produce exceptional returns because of its solid growth attributes.
Zacks·3d ago
News Placeholder
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Zacks·3d ago
News Placeholder
Will Positive Regulatory Updates Further Boost INCY Stock?
Incyte's strong 2025 performance is fueled by Jakafi's sustained growth and label expansion of Opzelura.
Zacks·5d ago
News Placeholder
NVS Reports Positive Late-Stage Data on Kidney Disease Drug
Novartis' Fabhalta shows strong phase III results in slowing IgA nephropathy progression, paving the way for full FDA approval in 2026.
Zacks·9d ago

Latest NVS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.